The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
No takes yet. Share an insight, caveat, or question.
Piscitelli et al. (1997) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: